Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 19%
Buy 31%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care has demonstrated a strong outlook, driven by a significant increase in pharmacy channel revenue, which accounted for 7% of US sales, reflecting a substantial sequential growth of approximately twofold. The company anticipates continued growth in US pump shipments at a rate of 10-11% year-over-year, with an optimistic shift towards positive new patient start growth due to enhanced access and conversions from multiple daily injections (MDIs). Additionally, projected revenue increases for 2026 and 2027 to $1.111 million and $1.229 million, respectively, further underscore the firm’s solid financial trajectory and expanding market potential.

Bears say

Tandem Diabetes Care is facing a negative outlook largely due to revised revenue expectations for 2026, which have been adjusted downwards to $1.07 billion, with projected negative EBITDA of -2% to -1% of revenue. The guidance for US revenue indicates a decline in new patient starts by an estimated 3% in 2025, compounded by a significant revenue headwind of $70–$80 million attributed to Pay-Go pump shipments. Additionally, various risks threaten the company’s profitability, including intensified competition, challenges in securing favorable pharmacy channel contracts, and uncertainties surrounding the growth potential of the newly launched Mobi pump.

TNDM has been analyzed by 16 analysts, with a consensus rating of Buy. 19% of analysts recommend a Strong Buy, 31% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 16 analysts, TNDM has a Buy consensus rating as of Apr 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.